BR112015024558A2 - método para tratamento de leucemia mieloide. - Google Patents
método para tratamento de leucemia mieloide.Info
- Publication number
- BR112015024558A2 BR112015024558A2 BR112015024558A BR112015024558A BR112015024558A2 BR 112015024558 A2 BR112015024558 A2 BR 112015024558A2 BR 112015024558 A BR112015024558 A BR 112015024558A BR 112015024558 A BR112015024558 A BR 112015024558A BR 112015024558 A2 BR112015024558 A2 BR 112015024558A2
- Authority
- BR
- Brazil
- Prior art keywords
- myeloid leukemia
- treating myeloid
- treating
- leukemia
- myeloid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361804677P | 2013-03-24 | 2013-03-24 | |
PCT/IL2014/050303 WO2014155376A1 (en) | 2013-03-24 | 2014-03-19 | Methods of treating myeloid leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015024558A2 true BR112015024558A2 (pt) | 2017-07-18 |
Family
ID=50483415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015024558A BR112015024558A2 (pt) | 2013-03-24 | 2014-03-19 | método para tratamento de leucemia mieloide. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20160082071A1 (pt) |
EP (1) | EP2978439B1 (pt) |
JP (1) | JP6294459B2 (pt) |
KR (1) | KR20150135432A (pt) |
CN (1) | CN105163749B (pt) |
AU (2) | AU2014240733B2 (pt) |
BR (1) | BR112015024558A2 (pt) |
CA (1) | CA2906314A1 (pt) |
ES (1) | ES2643321T3 (pt) |
HK (1) | HK1215790A1 (pt) |
IL (1) | IL240924B (pt) |
MX (1) | MX363896B (pt) |
WO (1) | WO2014155376A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010146578A2 (en) | 2009-06-14 | 2010-12-23 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
US20160243187A1 (en) * | 2013-10-31 | 2016-08-25 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
KR20210089270A (ko) | 2015-07-16 | 2021-07-15 | 바이오카인 테라퓨틱스 리미티드 | 암 치료용 조성물 및 방법 |
BR112018016924A2 (pt) * | 2016-02-23 | 2019-01-02 | Biokine Therapeutics Ltd | método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma |
US20190233524A1 (en) * | 2017-09-18 | 2019-08-01 | Tcm Biotech International Corp. | Therapeutic combination and method for treating cancer |
CN113150068B (zh) * | 2017-09-20 | 2023-04-04 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
US20210338767A1 (en) | 2018-09-25 | 2021-11-04 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
CA3117412A1 (en) * | 2018-10-29 | 2020-05-07 | Molecular Stethoscope, Inc. | Characterization of bone marrow using cell-free messenger-rna |
CN110935008B (zh) * | 2019-12-10 | 2023-09-26 | 昆明医科大学第一附属医院 | 一种关节腔注射治疗骨关节炎的tn14003温敏型凝胶及其制备方法 |
JP7441049B2 (ja) | 2020-01-15 | 2024-02-29 | カヤバ株式会社 | ギヤの製造方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US39282A (en) * | 1863-07-21 | Improvement in ch aim-shot | ||
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
JPS552602A (en) * | 1978-06-20 | 1980-01-10 | Yamasa Shoyu Co Ltd | 1-beta-d-arabinofranosylcytosine-5'-phosphoric acid oleyl ester |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
CA2421183C (en) | 2000-09-05 | 2015-06-16 | Seikagaku Corporation | Novel polypeptide and anti-hiv agent containing the same |
EP1541585B1 (en) | 2002-08-27 | 2013-01-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
JP4781621B2 (ja) * | 2002-08-27 | 2011-09-28 | バイオカイン セラピューティックス リミテッド | Cxcr4拮抗薬およびその用途 |
DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
WO2004087068A2 (en) | 2003-03-27 | 2004-10-14 | Emory University | Cxcr4 antagonists and methods of their use |
CN101365336B (zh) | 2005-08-19 | 2013-05-29 | 健赞股份有限公司 | 增强化疗的方法 |
-
2014
- 2014-03-19 AU AU2014240733A patent/AU2014240733B2/en active Active
- 2014-03-19 KR KR1020157030463A patent/KR20150135432A/ko not_active Application Discontinuation
- 2014-03-19 CN CN201480023972.0A patent/CN105163749B/zh active Active
- 2014-03-19 EP EP14717212.6A patent/EP2978439B1/en active Active
- 2014-03-19 WO PCT/IL2014/050303 patent/WO2014155376A1/en active Application Filing
- 2014-03-19 BR BR112015024558A patent/BR112015024558A2/pt not_active Application Discontinuation
- 2014-03-19 CA CA2906314A patent/CA2906314A1/en not_active Abandoned
- 2014-03-19 US US14/771,513 patent/US20160082071A1/en not_active Abandoned
- 2014-03-19 JP JP2016503780A patent/JP6294459B2/ja active Active
- 2014-03-19 MX MX2015013525A patent/MX363896B/es active IP Right Grant
- 2014-03-19 ES ES14717212.6T patent/ES2643321T3/es active Active
-
2015
- 2015-08-30 IL IL240924A patent/IL240924B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103738.3A patent/HK1215790A1/zh unknown
-
2018
- 2018-07-16 US US16/035,790 patent/US20180311308A1/en not_active Abandoned
- 2018-07-31 US US16/049,898 patent/US20180344801A1/en not_active Abandoned
-
2019
- 2019-01-18 AU AU2019200329A patent/AU2019200329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160082071A1 (en) | 2016-03-24 |
CN105163749A (zh) | 2015-12-16 |
WO2014155376A1 (en) | 2014-10-02 |
AU2014240733B2 (en) | 2018-11-22 |
CN105163749B (zh) | 2018-03-27 |
AU2014240733A1 (en) | 2015-10-22 |
JP2016516080A (ja) | 2016-06-02 |
IL240924A0 (en) | 2015-10-29 |
AU2019200329A1 (en) | 2019-02-07 |
HK1215790A1 (zh) | 2016-09-15 |
US20180311308A1 (en) | 2018-11-01 |
MX2015013525A (es) | 2016-07-18 |
IL240924B (en) | 2018-01-31 |
EP2978439B1 (en) | 2017-08-16 |
KR20150135432A (ko) | 2015-12-02 |
JP6294459B2 (ja) | 2018-03-14 |
CA2906314A1 (en) | 2014-10-02 |
US20180344801A1 (en) | 2018-12-06 |
EP2978439A1 (en) | 2016-02-03 |
MX363896B (es) | 2019-04-05 |
ES2643321T3 (es) | 2017-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292193A (en) | Anti-b7–h1 antibodies for the treatment of tumors | |
CL2016001080A1 (es) | Benzamidas sustituidas para tratamiento de artrópodos. | |
BR112015024558A2 (pt) | método para tratamento de leucemia mieloide. | |
HK1217974A1 (zh) | 處理動物基材的方法 | |
BR112016010220A2 (pt) | compostos inibidores de autoxatina. | |
BR112016022868A2 (pt) | método para preparação de amg 416. | |
BR112016021624A2 (pt) | indexação de locais baseada em polígono | |
BR112016010221A2 (pt) | inibidores tetracíclicos de autotaxina. | |
HK1250649A1 (zh) | 用於治療白血病的抗-s100a8 | |
BR112016029236A2 (pt) | métodos para tratar prurido. | |
EP3009131A4 (en) | Agents for treating multiple myeloma | |
FI20135921A (fi) | Menetelmä metallien käsittelemiseksi | |
SG11201507951SA (en) | Method for producing 2,7-octadien-1-ol | |
DK3016682T3 (da) | Metoder til behandling af kræft | |
HUE037141T2 (hu) | Eljárás 1,1-dibróm-1-fluoretán elõállítására | |
ES1079003Y (es) | Proyectil para aerosiembra selectiva. | |
BR112014028306A2 (pt) | métodos para tratamento de câncer gástrico. | |
EP2971018A4 (en) | BARLEY-BASED BIODEFFINATION PROCESS | |
ITUA20162547A1 (it) | Racla per additive manufacturing | |
ITUB20156794A1 (it) | Dispositivo portacasco perfezionato | |
FR3005864B1 (fr) | Procede de decontamination. | |
ES1115330Y (es) | Pinza - colgador, para cinturón. | |
FI20155772A (fi) | Menetelmä biolietteen käsittelemiseksi | |
ITUB201554763U1 (it) | Gruppo frizione per presa di forza | |
FR3018827B1 (fr) | Procede de vernissage de pieces metallisees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |